InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
0
T+90 胜率
100%
T+90 平均收益
+0.7%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
无可用的信号评分。
Explore the complete record of transactions filed by Bejar Rafael, Directeur Médical. Officer active across 1 company, notably Aptose Biosciences Inc.. Aggregated, 3 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €23k. Activity tracked since 19 November 2021. The latest transaction was filed on 19 January 2023 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Bejar Rafael
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
244 股Common SharesSEC:0000912282-26-000893:0
100,000 股0Common SharesSEC:0001567619-23-001153:0
10,000 股@ US$2.56100.0% 占其流量Common SharesSEC:0001567619-21-020906:0
标准退出：2022年2月17日 (T+90)
3 条申报中的 3 条
About Bejar Rafael
Rafael Bejar is the Chief Medical Officer at Aptose Biosciences Inc. He is responsible for the medical and scientific direction of the company, overseeing the development of new treatments and clinical research. His expertise in medicine and biotechnology is crucial for the innovation and success of the company. Rafael is committed to improving patient outcomes.
